Blog

(Source:Georgetown University Medical Center) Originally published Sep 27, 2022, Medical Life Sciences Giving immunotherapy before targeted therapy improves survival in…

(NEWS PROVIDED BY  Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…

(NEWS PROVIDED BY  Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…

(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…

Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…

(reprint from Business Wire, published: July 22, 2022) Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody…

(reimpresión de Biospace, publicado: 03 de junio de 2022) Immunocore anuncia la colaboración en un ensayo clínico con Sanofito para evaluar el candidato a producto de Sanofi SAR444245, IL-2 no alfa, en combinación con KIMMTRAK® en pacientes con...

(reprint from Targeted Oncology, published: Jun 05, 2022) Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II…

CONTACTO: Samantha Guild Presidenta AIM en la Fundación del Melanoma 916/206-6100 SGuild@AIMatMelanoma.org 19 de marzo de 2022 (Richmond, California) Ayer, Bristol Myers Squibb anunció...

26 de enero de 2022 (Richmond, California) En el día de hoy, Immunocore ha anunciado que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha aprobado KIMMTRAK...